Results from the data on psoriasis and RA suggested there may be enough evidence to pursue more research into inflammatory conditions and GLP-1 analogs
Daily doses increase to 1.8 mg in the third week, 2.4 mg in the fourth week, and 3 mg, the full dose, in the fifth and subsequent weeks of treatment
Diabetes Care 2017
Thus, exenatide treated patients maintained their cognitive benefit 12-months following drug cessation, however, it should be noted that cognitive scores also remained unchanged for controls between 12 and 24 months
doi: 10.1111/dom.14280 27 van CanJSlothBJensenCBFlintABlaakEESarisWH
Furthermore, a recent extensive cohort study involving over 33,000 GLP-1 RA users diagnosed with diabetes over a 9-year period indicated no significant increase in pancreatic cancer risk associated with GLP-1 RA use, as evidenced by an HR of 0.50 compared to basal insulin [60]